Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP)
在对度普利尤单抗治疗反应不足的成人和青少年中重度特应性皮炎患者中,从度普利尤单抗换用乌帕替尼:3b/4期研究(LEVEL UP)第2期疗效和安全性结果
期刊:American Journal of Clinical Dermatology
影响因子:8.8
doi:10.1007/s40257-025-01003-0
Bunick, Christopher G; Magnolo, Nina; Moore, Angela; Abe, Masatoshi; Gao, Xinghua; Lynde, Charles; Ibrahim, Nadia; Levy, Gweneth; Calimlim, Brian M; Wu, Xiaoqiang; Armendariz, Yolanda; Grada, Ayman; Eyerich, Kilian